Regular updates related to sourcing and the management of health products are available on this page.
-
13 February 2023
Opportunity for Evaluation of Pharmaceutical Products
The Global Fund invites manufacturers of pharmaceutical products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for pharmaceutical products (ERP). -
13 February 2023
Opportunity for Evaluation of Pharmaceutical Products – Antituberculosis Medicines
The Global Fund invites manufacturers of pharmaceutical products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for pharmaceutical products (ERP). This evaluation will focus particularly on Antit... -
19 October 2022
Opportunity for Evaluation of Diagnostic Products
The Global Fund and Unitaid are inviting manufacturers of diagnostic products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for Diagnostics (ERPD). -
18 July 2022
Placing Orders and Procuring Health Products for 2023
-
13 June 2022
Opportunity for Evaluation of Diagnostic Products – Syphilis Diagnosis
The Global Fund and Unitaid are inviting manufacturers of diagnostic products to submit an expression of interest to have their products evaluated by the Expert Review Panel for Diagnostics. -
20 May 2022
New Isoniazid/rifapentine and rifapentine generic for tuberculosis (TB) prevention recently recommended for use by ERP
The following products have been recommended for use by the Expert Review Panel (ERP): Rifapentine 300mg tablets Al/Al strip pack manufactured by Lupin, India; Rifapentine/Isoniazid 300/300mg Al/Al strip pack manufactured by Lupin, India